Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

March 14, 2016March 14, 2016

Possible Malignant Mesothelioma Treatment Target Might Be HOX Genes

News

HOX is a family of genes well–known to be dysregulated in several forms of cancer. British researchers now reported that the expression of HOX genes is also disrupted in malignant mesothelioma, ... Read more

March 10, 2016March 10, 2016

Advanced Pleural Mesothelioma Patients Show Improved Survival with Higher Doses of Amatuximab

News

Researchers at the European Knowledge Centre (EKC) and the National Cancer Institute, working collaboratively, showed that a higher amatuximab dose in malignant pleural mesothelioma (MPM) patients was associated with longer overall survival. The ... Read more

March 8, 2016March 8, 2016

Pleural Mesothelioma Vaccine, WT1, Named ‘Orphan Drug’ by FDA to Advance Its Development

News

SELLAS Life Sciences Group recently announced that the U.S. Food and Drug Administration (FDA) has granted the company’s WT1 cancer vaccine Orphan Drug Designation as a potential treatment for patients with malignant pleural mesothelioma ... Read more

March 4, 2016March 4, 2016

Idiopathic Pulmonary Fibrosis Deaths Seen to Be Linked to Asbestos Use in UK Study of 20th Century Data

News

British scientists have found a clear and lineal relationship between asbestos imported into the country and the number of annual deaths attributed to idiopathic pulmonary fibrosis (IPF). The more asbestos ... Read more

March 2, 2016March 2, 2016

Therapy for Advanced Mesothelioma, Tremelimumab, Fails to Improve Survival in Clinical Trial, Company Reports

News

AstraZeneca recently announced that the Phase 2b clinical trial evaluating tremelimumab monotherapy for the treatment of patients with unresectable malignant mesothelioma —the DETERMINE study — did not meet its primary endpoint of ... Read more

February 16, 2016February 16, 2016

For Mesothelioma Treatment, an Immunotherapy-Based Approach Holds Promise

News

A study published in the Journal of Translational Medicine showed that synthetic DNA sequences – called CpG-oligodeoxynucleotides (CpG-ODN) – can effectively halt the growth of human diffuse malignant peritoneal mesothelioma ... Read more

January 22, 2016January 22, 2016

Gene Mutation Found in Select Mesothelioma Patients Seen to Aid in Survival

News

A study investigating the frequency of BAP1 mutations in the germline of asbestos-exposed patients with mesothelioma and a family history of cancer reported that the mutations were found in 6 percent of the ... Read more

January 20, 2016January 20, 2016

In Mesothelioma Study, Flaxseed Diet Protected Mice Against Asbestos-Induced Inflammation

News

A new study published in the journal Carcinogenesis reported that mice fed a diet enriched with flaxseed lignan components were protected against asbestos-induced inflammation preceding the development of malignant mesothelioma (MM). Earlier studies have linked the inflammation and ... Read more

January 14, 2016January 14, 2016

New Two-Step Delivery System Has Potential to Increase Drug Concentration in Tumor

News

A new study reported on a novel method of increasing the concentration of anticancer drugs at the site of the tumor, exploring a two-step nanoparticle delivery system for mesothelioma and other similar cancers in ... Read more

January 11, 2016January 11, 2016

Mesothelioma in 2-Year-Old Presents a Rare Enigma

News

A case report of a 2-year-old boy, admitted to the hospital with a solitary benign fibrous mesothelioma (BFM) in the abdomen, was recently published in the Asian Journal of Surgery. The ... Read more